HOME ＞ 研究業績詳細
研究業績詳細
石川 大（イシカワ ダイ）
| 研究テーマ | IBDの治療、免疫異常、腸内細菌療法 |
|---|---|
| 研究業績（論文） | Shibuya T, Ishikawa D, et al. Recurrent local and systemic hypersensitivity reactions after switching back from subcutaneous to intravenous vedolizumab in ulcerative colitis: a case presentation. Gastroenterology Report, Volume 14, February 2026, goag048, Kentaro Ito, Dai Ishikawa, et al. Clinical and cytokine response to immunopure apheresis in patients with refractory ulcerative colitis: results from a single-center study. Ren Replace Ther 12, 27 (2026) Mariko Hojo, Dai Ishikawa, et al. Immediate discontinuation versus gradual tapering of proton pump inhibitors in long-term users: a randomized controlled trial. J Gastroenterol (2026) 27 April 2026 Akira Uchiyama, Dai Ishikawa, et al. Perceived Impact of a Junior-Senior Inpatient Team Model on Clinical Workflow, Supervision, and Workload in a Tertiary Gastroenterology Department: A Mixed-Methods Study. J Clin Med. 2026 Feb 21;15(4):1632 Zhang F, Ishikawa D, et al. Principles and Practice Guidelines of Microbiota Medicine: Statements From the CHINAGUT Conference. Microbiota Medicine Research, 2026; 00:1–9 Yoshinami Y, Ishikawa D, et al. Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer. Future Oncol. 2025 Dec 17:1-10. Takeshige-Amano H, Ishikawa D, et al. Randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of antibiotic faecal microbiota transplantation in patients with Parkinson's disease (FLORA-PD): a study protocol. BMJ Open. 2025 Oct 20;15(10):e102851. Maruyama T, Ishikawa D, et al. Hydrogen Gas Inhalation Improved Intestinal Microbiota in Ulcerative Colitis: A Randomised Double-Blind PlaceboControlled Trial. Biomedicines,2025 Jul;13(8):1799. Orikasa M, Ishikawa D, et al. Small-Bowel Capsule Endoscopy in Immune-Mediated Enterocolitis: A Case Series of Four Patients. JGH Open. 2025 Jun 18;9(6):e70201. Yamamoto M, Ishikawa D, et al. Primary aorto-enteric fistula diagnosed by double-balloon endoscopy. DEN Open. 2025 Apr 16;5(1):e70118. Ito K, Ishikawa D, et al. Diagnosis of small bowel inflammation using small bowel capsule endoscopy combined with abdominal CT scan. Endosc Int Open. 2025 Apr 4;13:a25604839. Ishikawa D, et al. Patient-donor similarity and donor-derived species contribute to the outcome of faecal microbiota transplantation for ulcerative colitis. J Crohns Colitis,2025 Apr;19(4):jjaf054. Faming Z, Ishikawa D, et al. Preferred Reporting Items for Microbiotherapy (PRIM) Guidelines Across Medical Disciplines: An International Delphi Consensus. Journal of Gastroenterology and Hepatology,2025 Mar; 40:1364-1373 Nakase H, Ishikawa D, et al. Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study. EBioMedicine. 2024 Dec;110:105454. Ishikawa D, et al. Anti-inflammatory effects of Bacteroidota strains derived from outstanding donors of fecal microbiota transplantation for the treatment of ulcerative colitis. Inflamm Bowel Dis. 2024 May;30(11):2136-2145. Nomura K, Ishikawa D, et al. Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study. Biomedicines. 2024 Sep 2;12(9):1991. Nomura K, Ishikawa D, et al. Small Intestinal Arteriovenous Malformation Treated by Double-balloon Endoscopy. Intern Med. 2024 Aug 1;63(15):2131-2135. Nomura K, Ishikawa D, et al. Residual Recurrence of a Small Intestinal Capillary Hemangioma with Obscure Gastrointestinal Bleeding Treated by Double-Balloon Endoscopy: A Case Report and Literature Review. J Clin Med. 2024 Jun 11;13(12):3415. Omori M, Ishikawa D, et al. Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan Biomedicines. 2024 May 17;12(5):1119. Yamashiro K, Ishikawa D, et al. Free water in gray matter linked to gut microbiota changes with decreased butyrate producers in Alzheimer’s disease and mild cognitive impairment. Neurobiol Dis. 2024 Apr;193:106464. Fukushima H, Ishikawa D, et al. Efficacy of Recurrence Prevention by Adjuvant Radiotherapy After Endoscopic Resection for Early Esophagus Cancer. American journal of gastroenterology. 2023;118(10S):p S377 Nomura K, Ishikawa D, et al. Enterolith Treated with a Combination of Double-Balloon Endoscopy and Cola Dissolution Therapy. Medicina, 2023 Mar 15; 59(3): 573. Nagai M, Ishikawa D, et al. High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection. Nat Commun. 30 Jun 2023;14(1):3863. Haga K, Ishikawa D, et al. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines. 2022; 10(10):2526 Shibuya T, Ishikawa D, et al. Efficacy of cytapheresis for induction therapy and extra-intestinal skin manifestations of ulcerative colitis. Ther Apher Dial. 2022; 26(3):522-528 X Zhang, D Ishikawa,et al. Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis. J. Clin. Med. 2022, 11(4), 1055; D Ishikawa, et al. A Randomized Placebo-Controlled Trial of Combination Therapy With Post-triple-antibiotic-therapy Fecal Microbiota Transplantation and Alginate for Ulcerative Colitis: Protocol. Front Med (Lausanne). 2022; 9:779205 Nakajima A, Ishikawa D, et al. Nicotine Oral Administration Attenuates DSS-Induced Colitis Through Upregulation of Indole in the Distal Colon and Rectum in Mice. Front Med (Lausanne). 2021 Dec 13;8:789037. Nishikawa Y, Ishikawa D, et. al. Long-term outcomes of antibiotic combination therapy for ulcerative colitis. Ther Adv Chronic Dis. 2021 Jul 6;12:20406223211028790. K Nomura, D Ishikawa, et al. Bacteroidetes Species Are Correlated with Disease Activity in Ulcerative Colitis. J Clin Med. 2021 April 17;10:1749. Koki Okahara, Dai Ishikawa,et al. Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Microbiota Transplantation. Received: 28 April 2020; Accepted: 28 May 2020; Published: 31 May 2020 Takahashi M, Ishikawa D, et al. Faecal freezing preservation period influences colonization ability for faecal microbiota transplantation. J Appl Microbiol. 2019 Mar;126(3):973-984. Ishikawa D, et al. The Microbial Composition of Bacteroidetes Species in Ulcerative Colitis Is Effectively Improved by Combination Therapy with Fecal Microbiota Transplantation and Antibiotics Inflamm Bowel Dis. 2018 Aug ;29;24(12):2590-2598 石川 大「総説：便移植の現状と展望」腸内細菌学雑誌2018 Jul 32:137-144 Ishikawa D. Fecal Microbiota Transplantation for the Treatment of Gastrointestinal Disease: Present and Future Prospects Gastroenterological Endoscopy. 2018 Apr ;60(4):969-980 Ishikawa D, et al. Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflamm Bowel Dis. 2017 Jan ;23(1):116-125. Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Ishikawa D, et al. Mucosal Immunol. 2012 Jul 11. doi: 10.1038/mi.2012.67. Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism. Corridoni D, Ishikawa D, et al. PLoS One. 2012;7(7):e42067. Epub 2012 Jul 25 |
| 研究者 | 教育活動 | researchmap(JST) | ホームページURL |